Milestone for FierceBiotech


Every now and then, we take time to toot our horn here at FierceBiotech. And this is one of those times.

This month, the daily biotech newsletter is reaching over 60,000 subscribers. We've begun a new weekly series on emerging biotechs and launched a redesigned website. We've also launched a new publication, FiercePharma, to extend our coverage of the life sciences industry. Now, with FierceBioResearcher, which has gained more than 16,000 subscribers, we cover every element of the drug industry, from the conception of new drugs through to approval--or disapproval--and on to post-marketing studies and market development. This fall I'll be attending conferences in Barcelona and Australia as well, which underscores our commitment to providing a global view of what's happening in life sciences.

Of course, as with any endeavor, this is a work in progress. With 80,000 total subscribers, we know we still have a long way to go. You suggestions, criticisms and praise are always appreciated. So keep those cards and letters and e-mails coming. I'm particularly interested in your suggestions for new webinars. We've attracted audiences of up to 450 people covering a broad range of issues and we're planning to do more this year with a full schedule for '08. - John Carroll

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.